{"groups":[{"description":"Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.","id":"FG000","title":"Peginterferon α-2b"},{"description":"Participants were observed and received no treatment","id":"FG001","title":"No Treatment"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"101"}],"type":"Relapse or Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"3"}],"type":"Serious Adverse Events"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Unable to Complete"},{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"5"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"123"},{"groupId":"FG001","numSubjects":"121"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"106"},{"groupId":"FG001","numSubjects":"112"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}